A 53-year-old man presents to his GP with 8 weeks of exertional chest tightness. He describes a pressure sensation across his chest occurring predictably during brisk walking uphill, relieved within 3-4 minutes of rest. He has type 2 diabetes, hypertension, and is an ex-smoker (quit 5 years ago, 20 pack-year history). Examination is unremarkable. Resting 12-lead ECG is normal. His blood pressure is 142/86 mmHg. What is the most appropriate initial investigation to establish the diagnosis?
Q62
A 69-year-old man with heart failure and reduced ejection fraction (LVEF 28%) on optimal medical therapy including ramipril, bisoprolol, spironolactone, and sacubitril-valsartan presents for device consideration. His ECG shows sinus rhythm with heart rate 68 bpm, QRS duration 158 ms with left bundle branch block morphology, and he remains NYHA class III despite maximal tolerated medical therapy. His blood pressure is 112/68 mmHg and eGFR 52 mL/min/1.73m². Which device therapy is most appropriate?
Q63
A 47-year-old woman from Pakistan presents with progressive dyspnoea over 2 years. Echocardiography shows thickened mitral valve leaflets with doming, restricted leaflet motion, commissural fusion, and a mitral valve area of 1.2 cm². There is moderate mitral regurgitation and mild subvalvular thickening. The left atrium is dilated at 5.2 cm. She is in atrial fibrillation with good rate control on bisoprolol. Her CHA₂DS₂-VASc score is 3. What is the most appropriate management strategy?
Q64
A 82-year-old woman is admitted with acute decompensated heart failure. She has severe symptomatic aortic stenosis with an aortic valve area of 0.7 cm², mean gradient 48 mmHg, and LVEF 32%. She has multiple comorbidities including COPD, previous stroke with residual left-sided weakness, and frailty. Her EuroSCORE II is 18%. After multidisciplinary team discussion, she is considered too high risk for surgical aortic valve replacement. What is the most appropriate management option?
Q65
A 74-year-old man with paroxysmal atrial fibrillation presents for anticoagulation review. He has hypertension treated with amlodipine, and had a transient ischaemic attack 18 months ago with full recovery. His CHA₂DS₂-VASc score is 5. He has no history of bleeding. Blood tests show: Hb 142 g/L, platelets 245 × 10⁹/L, creatinine 168 μmol/L, eGFR 34 mL/min/1.73m². Which anticoagulation option is most appropriate?
Q66
A 58-year-old woman with newly diagnosed heart failure and LVEF 35% has been established on ramipril 10 mg daily, bisoprolol 10 mg daily, and furosemide 40 mg daily. She remains symptomatic with NYHA class II-III symptoms. Her blood pressure is 118/68 mmHg, heart rate 64 bpm. Blood tests show sodium 138 mmol/L, potassium 4.4 mmol/L, creatinine 104 μmol/L, eGFR 56 mL/min/1.73m². She is in sinus rhythm. Which additional therapy would provide the greatest mortality benefit?
Q67
A 64-year-old man with ischaemic cardiomyopathy and LVEF of 30% is reviewed in the heart failure clinic. He was commenced on ramipril 2.5 mg daily 6 weeks ago, which was increased to 5 mg daily 3 weeks ago. His current blood pressure is 126/74 mmHg and heart rate 88 bpm. Blood tests show sodium 139 mmol/L, potassium 4.6 mmol/L, creatinine 98 μmol/L (baseline 92 μmol/L), eGFR 68 mL/min/1.73m². He remains mildly breathless on moderate exertion (NYHA class II). What is the most appropriate next step in his management?
Q68
A 71-year-old man presents with a 3-hour history of chest pain. His ECG shows ST-segment depression of 2 mm in leads V4-V6 and troponin I is elevated at 2850 ng/L (normal <40 ng/L). He has been commenced on aspirin, ticagrelor, fondaparinux, and intravenous morphine. His GRACE score is calculated at 142. He has stable observations with BP 135/82 mmHg, heart rate 78 bpm, and oxygen saturations 97% on room air. What is the most appropriate timeframe for coronary angiography?
Q69
A 61-year-old man with stable angina is being managed in the cardiology clinic. He experiences chest discomfort twice weekly during moderate exertion, relieved by rest within 5 minutes. He is currently taking aspirin 75 mg, atorvastatin 80 mg, and bisoprolol 5 mg once daily. His resting heart rate is 72 bpm and blood pressure is 128/76 mmHg. He reports that sublingual GTN provides good symptom relief. What is the most appropriate next step in optimising his antianginal therapy?
Q70
A 67-year-old man with type 2 diabetes and chronic kidney disease stage 3b (eGFR 38 mL/min/1.73m²) presents for cardiovascular risk assessment. He is currently taking metformin, ramipril, and atorvastatin 20 mg. His blood pressure is 134/78 mmHg. His lipid profile shows total cholesterol 4.8 mmol/L, LDL 2.6 mmol/L, HDL 1.1 mmol/L, non-HDL cholesterol 3.7 mmol/L. He achieved only a 32% reduction in non-HDL cholesterol from baseline. What modification to his lipid-lowering therapy is most appropriate?
Cardiology UK Medical PG Practice Questions and MCQs
Question 61: A 53-year-old man presents to his GP with 8 weeks of exertional chest tightness. He describes a pressure sensation across his chest occurring predictably during brisk walking uphill, relieved within 3-4 minutes of rest. He has type 2 diabetes, hypertension, and is an ex-smoker (quit 5 years ago, 20 pack-year history). Examination is unremarkable. Resting 12-lead ECG is normal. His blood pressure is 142/86 mmHg. What is the most appropriate initial investigation to establish the diagnosis?
A. Exercise tolerance test (ETT)
B. CT coronary angiography (CTCA) (Correct Answer)
C. Invasive coronary angiography
D. Stress echocardiography
E. Myocardial perfusion scintigraphy (MPS)
Explanation: ***CT coronary angiography (CTCA)***- According to **NICE guidelines (CG95)**, CTCA is the first-line investigation for patients with suspected **stable angina** who present with typical or atypical chest pain.- It provides high **negative predictive value** and can non-invasively identify **coronary artery disease (CAD)** or significant plaque burden in patients with metabolic risk factors like **diabetes**.*Exercise tolerance test (ETT)*- Current clinical guidelines no longer recommend ETT as the first-line test due to its **low sensitivity** and high rate of **false results**.- It is less reliable than imaging modalities for diagnosing obstructive **ischemic heart disease**.*Invasive coronary angiography*- This is an **invasive procedure** reserved for patients with high-risk features or those being considered for **revascularization**.- It is not indicated as an initial diagnostic tool when **non-invasive imaging** like CTCA can provide the diagnosis.*Stress echocardiography*- This is a **functional imaging** test used primarily if CTCA is technically difficult, contraindicated, or if imaging results are **inconclusive**.- It is not preferred over CTCA for the initial anatomical assessment of **coronary artery patency**.*Myocardial perfusion scintigraphy (MPS)*- Like stress echo, MPS is a **second-line functional test** used when anatomical imaging is not feasible or to assess the **significance of known stenoses**.- It involves **ionizing radiation** and is generally more resource-intensive than the primary recommendation of CTCA.
Question 62: A 69-year-old man with heart failure and reduced ejection fraction (LVEF 28%) on optimal medical therapy including ramipril, bisoprolol, spironolactone, and sacubitril-valsartan presents for device consideration. His ECG shows sinus rhythm with heart rate 68 bpm, QRS duration 158 ms with left bundle branch block morphology, and he remains NYHA class III despite maximal tolerated medical therapy. His blood pressure is 112/68 mmHg and eGFR 52 mL/min/1.73m². Which device therapy is most appropriate?
A. Implantable cardioverter-defibrillator (ICD) only
B. Cardiac resynchronisation therapy with defibrillator (CRT-D) (Correct Answer)
C. Cardiac resynchronisation therapy pacemaker (CRT-P) only
D. Permanent pacemaker with rate-response function
E. Continue medical therapy and reassess after 3 months
Explanation: ***Cardiac resynchronisation therapy with defibrillator (CRT-D)***
- The patient meets clear criteria for **CRT** due to an **LVEF ≤35%** (28%), **NYHA class III** symptoms, and a **QRS duration ≥150 ms** (158 ms) with **LBBB morphology** while in sinus rhythm, despite optimal medical therapy.
- A **defibrillator (CRT-D)** is essential because he is at high risk of sudden cardiac death and meets **primary prevention ICD** criteria with an LVEF ≤35%.
*Implantable cardioverter-defibrillator (ICD) only*
- An ICD alone provides protection against **ventricular arrhythmias** but does not address the underlying **mechanical dyssynchrony** caused by the wide QRS complex and LBBB.
- Without the **biventricular pacing** of CRT, the patient would likely remain highly symptomatic in NYHA class III, as the pump function remains inefficient.
*Cardiac resynchronisation therapy pacemaker (CRT-P) only*
- While CRT-P provides the necessary **biventricular pacing** to improve cardiac output and symptoms, it lacks the ability to terminate life-threatening ventricular arrhythmias with a **defibrillator**.
- CRT-P is typically reserved for patients who have contraindications to ICD implantation or those with an **anticipated short life expectancy** where the ICD benefit is less clear.
*Permanent pacemaker with rate-response function*
- A standard **single or dual-chamber pacemaker** is indicated for bradyarrhythmias, not for the treatment of systolic heart failure with significant dyssynchrony.
- Conventional right ventricular pacing can actually **worsen heart failure** by increasing ventricular dyssynchrony, which is already a problem in this patient.
*Continue medical therapy and reassess after 3 months*
- Guidelines recommend device consideration after **3 months of optimal medical therapy (OMT)**; this patient is already on maximal guideline-directed medical therapy including **sacubitril-valsartan** and remains symptomatic.
- Delaying intervention in a patient already on **quadruple therapy** with persistent severe dysfunction (LVEF 28%) and marked dyssynchrony would be inappropriate as he has met indications for advanced therapy.
Question 63: A 47-year-old woman from Pakistan presents with progressive dyspnoea over 2 years. Echocardiography shows thickened mitral valve leaflets with doming, restricted leaflet motion, commissural fusion, and a mitral valve area of 1.2 cm². There is moderate mitral regurgitation and mild subvalvular thickening. The left atrium is dilated at 5.2 cm. She is in atrial fibrillation with good rate control on bisoprolol. Her CHA₂DS₂-VASc score is 3. What is the most appropriate management strategy?
A. Percutaneous mitral balloon valvuloplasty
B. Surgical mitral valve replacement (Correct Answer)
C. Medical management with diuretics and anticoagulation only
D. Surgical mitral valve repair
E. MitraClip percutaneous mitral valve repair
Explanation: ***Surgical mitral valve replacement***- The patient has severe **mitral stenosis** (MVA 1.2 cm²) and **moderate mitral regurgitation** with significant rheumatic changes (subvalvular thickening, commissural fusion), necessitating intervention.- In such complex **rheumatic mitral valve disease** with significant regurgitation and subvalvular involvement, **surgical mitral valve replacement** offers the most durable and effective hemodynamic outcome.*Percutaneous mitral balloon valvuloplasty*- This procedure is contraindicated in patients with **moderate to severe mitral regurgitation** or significant **subvalvular disease**, both of which are present here.- A high **Wilkins score** (suggested by subvalvular thickening and leaflet changes) predicts poor outcomes and a high risk of procedural failure for balloon dilation.*Medical management with diuretics and anticoagulation only*- While diuretics and anticoagulation manage symptoms and prevent **thromboembolism** in atrial fibrillation, they do not address the **mechanical obstruction** of the mitral valve.- Conservative management alone is insufficient for a symptomatic patient with a **mitral valve area** of 1.2 cm² (moderate/severe stenosis) and progressive dyspnea.*Surgical mitral valve repair*- Surgical repair is technically difficult in **rheumatic mitral disease** because the valve tissue is often scarred, thickened, and prone to further calcification.- Repair is less durable than **replacement** in the setting of rheumatic fever, frequently leading to recurrent stenosis or regurgitation.*MitraClip percutaneous mitral valve repair*- **MitraClip** is specifically indicated for primary or secondary **mitral regurgitation**, not for treating **mitral stenosis** or commissural fusion.- Applying a clip to a stenotic valve would further reduce the **mitral valve area**, severely worsening the patient's condition.
Question 64: A 82-year-old woman is admitted with acute decompensated heart failure. She has severe symptomatic aortic stenosis with an aortic valve area of 0.7 cm², mean gradient 48 mmHg, and LVEF 32%. She has multiple comorbidities including COPD, previous stroke with residual left-sided weakness, and frailty. Her EuroSCORE II is 18%. After multidisciplinary team discussion, she is considered too high risk for surgical aortic valve replacement. What is the most appropriate management option?
A. Medical management with diuretics and afterload reduction
B. Transcatheter aortic valve implantation (TAVI) (Correct Answer)
C. Balloon aortic valvuloplasty as definitive treatment
D. Palliative care without further intervention
E. Ross procedure (pulmonary autograft)
Explanation: ***Transcatheter aortic valve implantation (TAVI)***
- **TAVI** is the preferred treatment for patients with **severe symptomatic aortic stenosis** who are deemed **high or prohibitive surgical risk** (EuroSCORE II 18%, frailty, and comorbidities).
- Clinical trials have proven that TAVI significantly improves **survival outcomes** and quality of life compared to medical management in patients unsuitable for surgery.
*Medical management with diuretics and afterload reduction*
- Medical therapy provides only symptomatic relief and does not address the mechanical obstruction, resulting in a **50% 2-year mortality** rate for severe AS.
- **Vasodilators** used for afterload reduction must be used with extreme caution in severe AS as they can cause severe **hypotension** and syncope.
*Balloon aortic valvuloplasty as definitive treatment*
- This procedure is typically used only as a **bridge to TAVI** or surgery because it has a very **high rate of restenosis** within 6-12 months.
- It is not considered a **definitive treatment** due to its lack of long-term mortality benefit compared to valve replacement.
*Palliative care without further intervention*
- While the patient is frail, palliative care is only suggested if the patient’s **quality of life** is not expected to improve or if life expectancy is **less than one year** despite TAVI.
- Given the acute decompensation, TAVI offers a potentially life-saving intervention that addresses the primary cause of her **heart failure**.
*Ross procedure (pulmonary autograft)*
- This is a complex surgery involving the transplantation of the patient's own **pulmonary valve** to the aortic position, which is far too invasive for a high-risk 82-year-old.
- It is primarily reserved for **younger patients** or children to avoid the long-term complications of prosthetic valves and allow for growth.
Question 65: A 74-year-old man with paroxysmal atrial fibrillation presents for anticoagulation review. He has hypertension treated with amlodipine, and had a transient ischaemic attack 18 months ago with full recovery. His CHA₂DS₂-VASc score is 5. He has no history of bleeding. Blood tests show: Hb 142 g/L, platelets 245 × 10⁹/L, creatinine 168 μmol/L, eGFR 34 mL/min/1.73m². Which anticoagulation option is most appropriate?
A. Warfarin with target INR 2.0-3.0
B. Apixaban 5 mg twice daily
C. Apixaban 2.5 mg twice daily (Correct Answer)
D. Rivaroxaban 20 mg once daily
E. Edoxaban 60 mg once daily
Explanation: ***Apixaban 2.5 mg twice daily***
- Apixaban requires a dose reduction to 2.5 mg twice daily if a patient meets two of three criteria: **age ≥80**, **weight ≤60 kg**, or **serum creatinine ≥133 μmol/L**.
- While this patient only strictly meets the **creatinine criterion** (168 μmol/L) based on the data provided, clinical guidelines often favor the **2.5 mg dose** in patients with significant **renal impairment** (eGFR 34 mL/min) to balance **stroke prevention** and **bleeding risk**.
*Warfarin with target INR 2.0-3.0*
- While effective, **Direct Oral Anticoagulants (DOACs)** are now generally preferred over **Warfarin** for non-valvular atrial fibrillation because they require less monitoring and have a better safety profile regarding **intracranial hemorrhage**.
- Warfarin remains a valid option in **severe renal failure** (eGFR <15 mL/min), but since this patient's **eGFR is 34 mL/min**, a DOAC is usually the first-choice recommendation.
*Apixaban 5 mg twice daily*
- The standard **5 mg dose** may increase the risk of bleeding in this patient due to his **elevated creatinine** (168 μmol/L) and reduced **eGFR (34 mL/min)**.
- Prescribing decisions for apixaban must carefully account for guidelines regarding **renal function** and metabolic clearance to avoid **drug accumulation** and adverse events.
*Rivaroxaban 20 mg once daily*
- The standard dose of **20 mg** is inappropriate for patients with a **CrCl between 15-49 mL/min**.
- For a patient with an **eGFR of 34 mL/min**, a reduced dose of **15 mg once daily** would be required if Rivaroxaban were the chosen agent.
*Edoxaban 60 mg once daily*
- Similar to other DOACs, the standard **60 mg dose** must be reduced to **30 mg once daily** if the **CrCl is between 15-50 mL/min**.
- Using the full dose in the context of an **eGFR of 34 mL/min** significantly increases the **bioavailability** of the drug and the subsequent risk of **major bleeding**.
Question 66: A 58-year-old woman with newly diagnosed heart failure and LVEF 35% has been established on ramipril 10 mg daily, bisoprolol 10 mg daily, and furosemide 40 mg daily. She remains symptomatic with NYHA class II-III symptoms. Her blood pressure is 118/68 mmHg, heart rate 64 bpm. Blood tests show sodium 138 mmol/L, potassium 4.4 mmol/L, creatinine 104 μmol/L, eGFR 56 mL/min/1.73m². She is in sinus rhythm. Which additional therapy would provide the greatest mortality benefit?
A. Add spironolactone 25 mg once daily (Correct Answer)
B. Add ivabradine 5 mg twice daily
C. Add digoxin 125 mcg once daily
D. Replace ramipril with sacubitril-valsartan 24/26 mg twice daily
E. Add hydralazine 25 mg three times daily and isosorbide dinitrate 20 mg three times daily
Explanation: ***Add spironolactone 25 mg once daily***
- In patients with **HFrEF** (LVEF ≤ 35%) who remain symptomatic despite optimal doses of an **ACE inhibitor** and **beta-blocker**, adding a **Mineralocorticoid Receptor Antagonist (MRA)** like spironolactone provides a significant **mortality benefit**.
- This patient satisfies the initiation criteria as her **potassium** is < 5.0 mmol/L and **eGFR** is > 30 mL/min/1.73m².
*Add ivabradine 5 mg twice daily*
- **Ivabradine** is indicated for symptomatic HFrEF only if the patient is in **sinus rhythm** with a resting heart rate **≥ 70 bpm** (or ≥ 75 bpm per some guidelines) despite maximum tolerated beta-blockers.
- Since this patient's heart rate is already well-controlled at **64 bpm**, ivabradine would not be appropriate or beneficial.
*Add digoxin 125 mcg once daily*
- **Digoxin** can be used to improve symptoms and reduce the rate of **hospitalization** in patients with worsening heart failure.
- However, it has not been shown to provide a **mortality benefit** in clinical trials like the DIG trial.
*Replace ramipril with sacubitril-valsartan 24/26 mg twice daily*
- **Sacubitril-valsartan (ARNI)** is a potent therapy, but clinical guidelines traditionally recommend adding an **MRA** first if the patient is still on a stable dose of ACEi/ARB.
- Initiating an ARNI requires a mandatory **36-hour washout period** from ramipril to avoid the risk of **angioedema**.
*Add hydralazine 25 mg three times daily and isosorbide dinitrate 20 mg three times daily*
- The combination of **hydralazine and isosorbide dinitrate** is specifically recommended for **Black patients** with NYHA class III-IV symptoms as an adjunct therapy.
- For other patients, it is typically reserved as an alternative when **ACE inhibitors or ARBs** are not tolerated due to renal impairment or hyperkalemia.
Question 67: A 64-year-old man with ischaemic cardiomyopathy and LVEF of 30% is reviewed in the heart failure clinic. He was commenced on ramipril 2.5 mg daily 6 weeks ago, which was increased to 5 mg daily 3 weeks ago. His current blood pressure is 126/74 mmHg and heart rate 88 bpm. Blood tests show sodium 139 mmol/L, potassium 4.6 mmol/L, creatinine 98 μmol/L (baseline 92 μmol/L), eGFR 68 mL/min/1.73m². He remains mildly breathless on moderate exertion (NYHA class II). What is the most appropriate next step in his management?
A. Continue ramipril 5 mg and review in 3 months
B. Increase ramipril to 10 mg daily
C. Add bisoprolol starting at 1.25 mg once daily (Correct Answer)
D. Add spironolactone 25 mg once daily
E. Add sacubitril-valsartan 24/26 mg twice daily
Explanation: ***Add bisoprolol starting at 1.25 mg once daily***
- For patients with **HFrEF** (LVEF < 40%), clinical guidelines recommend initiating both an **ACE inhibitor** and a **beta-blocker** as first-line foundational therapy.
- Since the patient is stable on ramipril and has an elevated heart rate of **88 bpm**, adding a low-dose beta-blocker is the most important next step to reduce **mortality** and **hospitalization** risk.
*Continue ramipril 5 mg and review in 3 months*
- This approach is inappropriate as the patient remains symptomatic (**NYHA class II**) and is currently missing a life-prolonging **beta-blocker**.
- Heart failure management requires active **up-titration** and addition of core medications rather than passive monitoring when the patient is not on optimal therapy.
*Increase ramipril to 10 mg daily*
- While increasing the ACE inhibitor to the **target dose** is eventually necessary, guidelines prioritize initiating both an ACE inhibitor and a **beta-blocker** first over maximum titration of one agent alone.
- Introducing the beta-blocker now will better address the patient's **resting tachycardia** and provide additional sympathetic blockade benefit.
*Add spironolactone 25 mg once daily*
- **Mineralocorticoid receptor antagonists (MRAs)** like spironolactone are typically added as the third-line step for patients who remain symptomatic despite optimal doses of **ACE inhibitors** and **beta-blockers**.
- The patient must first be established on the foundational **beta-blocker** therapy before advancing to MRA treatment.
*Add sacubitril-valsartan 24/26 mg twice daily*
- **ARNI** therapy (sacubitril-valsartan) is indicated as a **replacement** for an ACE inhibitor or ARB in patients who remain symptomatic despite an optimal dose of ACEI/ARB **and** a beta-blocker.
- It is not indicated at this stage because the patient has not yet been started on a **beta-blocker**, which is a prerequisite for transition to ARNI.
Question 68: A 71-year-old man presents with a 3-hour history of chest pain. His ECG shows ST-segment depression of 2 mm in leads V4-V6 and troponin I is elevated at 2850 ng/L (normal <40 ng/L). He has been commenced on aspirin, ticagrelor, fondaparinux, and intravenous morphine. His GRACE score is calculated at 142. He has stable observations with BP 135/82 mmHg, heart rate 78 bpm, and oxygen saturations 97% on room air. What is the most appropriate timeframe for coronary angiography?
A. Immediate angiography within 2 hours
B. Urgent angiography within 24 hours (Correct Answer)
C. Early angiography within 72 hours
D. Angiography during the same hospital admission before discharge
E. Outpatient angiography within 2 weeks if symptoms persist
Explanation: ***Urgent angiography within 24 hours***- This patient is diagnosed with an **NSTEMI** (ST-segment depression, elevated troponin) and has a **GRACE score of 142**, classifying him as **high risk** (GRACE >140).- Current clinical guidelines recommend an **urgent invasive strategy** within 24 hours for patients with NSTEMI and high-risk features like dynamic ST-segment changes or a high GRACE score.*Immediate angiography within 2 hours*- This timeframe is reserved for **very high-risk** patients exhibiting **hemodynamic instability**, cardiogenic shock, life-threatening arrhythmias, or refractory chest pain.- This patient is currently **stable** with normal vital signs and no signs of acute heart failure or ongoing ischemia.*Early angiography within 72 hours*- This timeframe is appropriate for **intermediate-risk** patients with a GRACE score typically between 109 and 140.- Since this patient's GRACE score is **142**, he falls into the high-risk category and requires a more accelerated intervention than the 72-hour window.*Angiography during the same hospital admission before discharge*- This approach is generally reserved for **low-risk** patients (GRACE <109) who do not have high-risk features.- For a high-risk NSTEMI, delaying angiography to this extent is associated with a higher rate of **recurrent ischemic events** and worse outcomes.*Outpatient angiography within 2 weeks if symptoms persist*- This is inappropriate for an acute presentation of **NSTEMI** with elevated cardiac biomarkers and significant ECG changes.- Acute coronary syndromes require **inpatient management** and prompt invasive risk stratification.
Question 69: A 61-year-old man with stable angina is being managed in the cardiology clinic. He experiences chest discomfort twice weekly during moderate exertion, relieved by rest within 5 minutes. He is currently taking aspirin 75 mg, atorvastatin 80 mg, and bisoprolol 5 mg once daily. His resting heart rate is 72 bpm and blood pressure is 128/76 mmHg. He reports that sublingual GTN provides good symptom relief. What is the most appropriate next step in optimising his antianginal therapy?
A. Increase bisoprolol to 10 mg once daily (Correct Answer)
B. Add amlodipine 5 mg once daily
C. Add ivabradine 5 mg twice daily
D. Add isosorbide mononitrate 30 mg once daily
E. Add nicorandil 10 mg twice daily
Explanation: ***Increase bisoprolol to 10 mg once daily***
- According to guidelines, the initial step in managing stable angina is to **titrate the first-line antianginal agent** (beta-blocker) to its maximum tolerated dose to achieve optimal symptom control.
- The patient's resting heart rate of **72 bpm** is above the optimal target range (typically 55-60 bpm for angina relief), indicating room for further dose escalation to reduce myocardial oxygen demand and improve symptoms.
*Add amlodipine 5 mg once daily*
- Adding a second antianginal agent like a **calcium channel blocker** is generally considered only after the initial first-line medication (beta-blocker) has been titrated to its **maximum tolerated dose**.
- As the bisoprolol dose has not yet been optimized, introducing an additional drug at this stage is premature and could increase the risk of adverse effects.
*Add ivabradine 5 mg twice daily*
- **Ivabradine** is typically reserved for patients who cannot tolerate or have contraindications to beta-blockers, or whose heart rate remains elevated (**>70 bpm**) despite receiving the **maximum tolerated dose** of beta-blockers.
- Since the current beta-blocker dose has not been maximized, ivabradine is not the most appropriate immediate next step in therapy optimization.
*Add isosorbide mononitrate 30 mg once daily*
- **Long-acting nitrates** are generally considered **second-line** agents for angina symptom control, typically added if symptoms persist despite optimized beta-blocker and/or calcium channel blocker therapy.
- Optimizing the existing beta-blocker is the preferred approach before introducing nitrates, which carry their own side effects like **headaches** and potential for **nitrate tolerance**.
*Add nicorandil 10 mg twice daily*
- **Nicorandil** is typically used as a **third-line** antianginal agent or as an alternative when other therapies are insufficient or contraindicated.
- Given that the patient's existing beta-blocker has not been titrated to its maximum effective dose, adding nicorandil is not the most appropriate next step in optimizing therapy.
Question 70: A 67-year-old man with type 2 diabetes and chronic kidney disease stage 3b (eGFR 38 mL/min/1.73m²) presents for cardiovascular risk assessment. He is currently taking metformin, ramipril, and atorvastatin 20 mg. His blood pressure is 134/78 mmHg. His lipid profile shows total cholesterol 4.8 mmol/L, LDL 2.6 mmol/L, HDL 1.1 mmol/L, non-HDL cholesterol 3.7 mmol/L. He achieved only a 32% reduction in non-HDL cholesterol from baseline. What modification to his lipid-lowering therapy is most appropriate?
A. Add ezetimibe 10 mg once daily
B. Continue current dose of atorvastatin as target achieved
C. Increase atorvastatin to 40 mg once daily (Correct Answer)
D. Switch to rosuvastatin 20 mg once daily
E. Add fenofibrate 200 mg once daily
Explanation: ***Increase atorvastatin to 40 mg once daily***
- NICE guidelines recommend aiming for at least a **40% reduction in non-HDL cholesterol** for cardiovascular risk reduction; this patient has only achieved a **32% reduction**.
- Dose escalation of the current statin is the preferred first step before adding secondary agents, and **atorvastatin 40 mg** is safe in patients with **CKD stage 3b (eGFR 38)**.
*Add ezetimibe 10 mg once daily*
- This agent is typically reserved for patients who have already reached the **maximum tolerated dose** of a statin or are intolerant to statins.
- Since the patient is only on **20 mg atorvastatin**, there is room to increase the statin dose first to achieve the treatment target.
*Continue current dose of atorvastatin as target achieved*
- The non-HDL cholesterol reduction is currently **32%**, which falls short of the recommended target of **>40%** reduction from baseline.
- In patients with high cardiovascular risk factors like **CKD and diabetes**, achieving target lipid levels is crucial for secondary prevention outcomes.
*Switch to rosuvastatin 20 mg once daily*
- Switching statins is generally indicated only if the patient experiences **intolerable side effects** or fails to respond despite dose titration.
- **Rosuvastatin** requires careful dosing and dose limits in patients with **renal impairment**, whereas atorvastatin is better tolerated in chronic kidney disease.
*Add fenofibrate 200 mg once daily*
- Fenofibrates are primarily used for severe **hypertriglyceridaemia** and do not provide the same cardiovascular risk reduction as statins.
- Fibrates carry an increased risk of **myopathy** when combined with statins and require extreme caution or are contraindicated in **chronic kidney disease**.
